Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

TCRX

+ Watchlist+ Portfolio

TScan Therapeutics, Inc.

Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$0.15
52-Week Range
$0.14 – $1.47
Market Cap
$10.06M
P/E (TTM)
—
EPS (TTM)
-0.89
Dividend Yield
0.00%
Advanced Metrics
Price/Book
0.07
PEG Ratio
—
Return on Equity
-95.80%
Return on Assets
-31.53%
Gross Margin
0.00%
Operating Margin
-1667.02%
Profit Margin
0.00%
Current Ratio
3.37
Debt/Equity
1.32
Total Debt
$90.89M
Free Cash Flow
$-79.92M
Revenue Growth
-65.80%
Earnings Growth
—
Enterprise Value
$2.12M

Market Snapshot

About

TScan Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing T cell receptor-engineered T cell (TCR-T) therapies for the treatment of cancer. The company uses its proprietary technology platform to identify novel cancer targets and engineer T cells to recognize and destroy tumor cells. TScan focuses on addressing both solid tumors and hematologic malignancies.